fedratinib (Inrebic) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Fedratinib (SAR-302503, TG-101348) is a selective small-molecule inhibitor of Janus kinase-2. Fedratinib demonstrated therapeutic efficacy in a murine model of myeloproliferative disease. Sanofi was developing Fedratinib for the treatment of myeloproliferative diseases and solid tumors. The clinical development of fedratinib was terminated after reports of Wernicke's encephalopathy in myelofibrosis patients.   NCATS

  • Mol. Mass: 524.678
  • ALogP: 4.82
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$128.0081 - $167.0854
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

fedratinib | n-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino) pyrimidin-4-ylamino)benzenesulfonamide | sar302503 | sar-302503 | tg101348 | tg-101348


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue